Ocuphire Pharma Stock News

Healthcare > Biotechnology

Buy OCUP

*Your capital is at risk

$1.17

+0 (+0%)

At Close: Jan 22, 2025

Ocuphire Initiates Enrollment in VEGA-1 Phase 2 Trial Investigating Nyxol in Presbyopia

08:53am, Thursday, 18'th Feb 2021

Nyxol and Low-Dose (0.4%) Pilocarpine Combination to Target Improvement in Near Vision in a Presbyopic Population

Ocuphire to Participate in the 2021 BIO CEO & Investor Conference and Cantor Fitzgerald's Panel on Eyeing Key Events in the Ophthalmology Space in 2021

09:13am, Thursday, 11'th Feb 2021

FARMINGTON HILLS, Mich., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapi

Ocuphire Announces Publication of ORION-1 Phase 2 Results for Nyxol in Clinical Ophthalmology and Presentation at the January OIS Presbyopia Innovation Showcase

07:00am, Wednesday, 20'th Jan 2021

Durability of Nyxol's Pupil Constricting Effects Using an Evening Dosing Regimen Informs Dosing Strategy for Phase 2 Trial in Presbyopia and Phase 3 Trial in NVD

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by